OTCMKTS:MCUJF Medicure Q2 2025 Earnings Results & Report $2.76 -0.04 (-1.43%) As of 10/14/2026 03:58 PM Eastern Medicure reported Q2 2025 earnings on August 20, 2025. The company reported EPS of -$0.06, while revenue was $4.82 million. Research:ProfileEarnings History Earnings Announcement Details QuarterQ2 2025Report DateAugust 20, 2025TimeAfter Market Closes Medicure EPS ResultsActual EPS-$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMedicure Revenue ResultsActual Revenue$4.82 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMedicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Medicure Q2 2025 Earnings FAQ Did Medicure beat earnings estimates for Q2 2025? Medicure (OTCMKTS:MCUJF) reported earnings of -$0.06 per share for Q2 2025. The report was announced on Wednesday, August 20, 2025. What was Medicure's revenue for Q2 2025? Medicure reported revenue of $4.82 million for Q2 2025. When is Medicure's next earnings date? Medicure's next earnings date is estimated for Thursday, November 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Medicure on the company's earnings history page. Medicure Earnings HeadlinesMedicure (OTCMKTS:MCUJF) Stock Crosses Above 50 Day Moving Average - What's Next?October 10, 2026 | americanbankingnews.comMEDICURE : ANNOUNCES GRANT OF STOCK OPTIONSOctober 1, 2026 | marketscreener.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical TrialSeptember 28, 2026 | finanznachrichten.deMedicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...May 26, 2026 | finance.yahoo.comMedicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference CallMay 21, 2026 | finanznachrichten.deSee More Medicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email. Email Address About MedicureMedicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company is headquartered in Winnipeg, Manitoba, and has concentrated its commercial activities on products intended for use in hospital and acute-care settings. Medicure’s principal product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the management of certain patients with acute coronary syndrome and other cardiovascular conditions. The product is designed to inhibit platelet aggregation and is marketed primarily through Medicure’s U.S. operations, with the company also pursuing opportunities in other markets where appropriate. Medicure has historically maintained a focus on cardiovascular drug development, commercialization, and licensing. The company is led by Dr. Albert D. Friesen, who has served as its president and chief executive officer. Medicure’s shares trade in Canada and in the United States under the symbol MCUJF.View Medicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
